Table 1.
Patient baseline demographic and clinical characteristics
| Variables | RT + PD1, N = 37 (%) | TACE + Sorafenib, N = 41(%) | P value |
|---|---|---|---|
| RT + PD1 versus TACE + sorafenib | |||
| Gender, male | 35(94.60%) | 37(90.24%) | 0.678 |
| Age, year | 54.16 ± 10.68 | 51.71 ± 9.571 | 0.288 |
| Bodyweight,kg | 63.58 ± 9.96 | 65.06 ± 10.84 | 0.534 |
| Hepatitis B, present | 31(83.78%) | 30(73.17%) | 0.286 |
| Hepatitis C, present | 1(2.70%) | 5(12.2%) | 0.204 |
| Liver cirrhosis, present | 17(45.95%) | 26(63.41%) | 0.171 |
| Alpha fetoprotein, ≥ 400 ng/ml | 18(48.65%) | 18(43.90%) | 0.820 |
| ALBI grade, ≤ 2 | 36 (97.3%) | 38 (93.7%) | 0.617 |
| Blood bilirubin, > 21umol/L | 9(24.32%) | 14(34.15%) | 0.457 |
| Albumin, < 35 g/L | 17(45.95%) | 31(75.61%) | 0.010 |
| Hemoglobin, < 131 g/L | 22(59.46%) | 19(46.34%) | 0.266 |
| Platelet count, < 100*109/L | 7(18.92%) | 6(14.63%) | 0.763 |
| White blood cell, < 3.97*109/L | 7(18.92%) | 4(9.76%) | 0.333 |
| Maximum tumor diameter, cm | 7.30(4.75–8.65) | 6.20(4.15–10.80) | 0.860 |
| Maximum tumor diameter, ≥ 10 cm | 8(21.62%) | 13(31.71%) | 0.444 |
| Macrovascular invasion, present | 16(43.24%) | 24(58.54%) | 0.257 |
| Extrahepatic metastasis,present | 22(59.46%) | 14(34.15%) | 0.040 |
| BCLC stage | 0.147 | ||
| B | 4(10.81%) | 10(24.39%) | |
| C | 33(89.19%) | 31(75.61%) | |
| Prior therapy | |||
| TACE, present | 11(29.73%) | 10(24.39%) | 0.619 |
| Hepatectomy, present | 16(43.24%) | 14(34.15%) | 0.487 |
| Systemic therapy, present | 6(16.22%) | 6(14.63%) | 1.000 |
Data are mean ± standard deviation, median (IQR) or N (%)
RT Radiotherapy; PD1 The monoclonal antibody against programmed cell death 1; TACE Transcatheter arterial chemoembolization; ALBI Albumin–bilirubin; BCLC Barcelona Clinic Liver Cancer